Septerna CMO granted 275,000 stock options

Septerna, Inc. (SEPN) reported that Chief Medical Officer Rajiv Patni received a grant of stock options for 275,000 shares of common stock on September 8, 2026, at an exercise price of $37.37 per share, expiring on September 7, 2036.

Rhea-AI Filing Summary

Septerna, Inc. (SEPN) reported that Chief Medical Officer Rajiv Patni received a grant of stock options for 275,000 shares of common stock on September 8, 2026, at an exercise price of $37.37 per share, expiring on September 7, 2036. According to the vesting terms, 25% of the underlying shares vest on August 24, 2027 and the remaining 75% vest in thirty-six substantially equal monthly installments thereafter, subject to his continuous service, resulting in reported holdings of 275,000 options after this grant.

Insider Trade Summary

Grant/Award: 275,000 shares

Grant/Award 1 txn

Insider Patni Rajiv

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	275,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 275,000 contracts (Direct)

Footnotes (1)

1. F1. 25% of the shares underlying this option will vest on August 24, 2027, and the remaining 75% of the shares underlying this option will vest in thirty-six substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Key Figures

Stock options granted: 275,000 options Exercise price: $37.37 per share Initial vesting portion: 25% of underlying shares +3 more

6 metrics

Stock options granted 275,000 options Grant to Chief Medical Officer Rajiv Patni on September 8, 2026

Exercise price $37.37 per share Exercise price of the 275,000-share stock option grant

Initial vesting portion 25% of underlying shares Vests on August 24, 2027, subject to continuous service

Remaining vesting portion 75% of underlying shares Vests in thirty-six substantially equal monthly installments after August 24, 2027

Expiration date September 7, 2036 Expiration of the stock option grant

Options held after grant 275,000 options Total options reported for this award following the transaction

Key Terms

vest, substantially equal monthly installments, continuous service

3 terms

vest financial

"25% of the shares underlying this option will vest on August 24, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

substantially equal monthly installments financial

"will vest in thirty-six substantially equal monthly installments thereafter"

continuous service financial

"subject to the Reporting Person's continuous service to the Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Septerna (SEPN) disclose about Rajiv Patni’s new equity grant?

Septerna disclosed that Chief Medical Officer Rajiv Patni received stock options for 275,000 shares of common stock on September 8, 2026, with an exercise price of $37.37 per share and an expiration date of September 7, 2036.

How do the 275,000 Septerna (SEPN) stock options granted to Rajiv Patni vest?

For Rajiv Patni’s 275,000-share option grant, 25% of the underlying shares vest on August 24, 2027. The remaining 75% vest in thirty-six substantially equal monthly installments thereafter, subject to his continuous service to Septerna on each vesting date.

What is the exercise price and term of Rajiv Patni’s Septerna (SEPN) option grant?

The option grant to Rajiv Patni carries an exercise price of $37.37 per share and an expiration date of September 7, 2036, giving him the right to purchase Septerna common stock at that price until that date, subject to vesting.

How many Septerna (SEPN) options does Rajiv Patni hold after this transaction?

After this reported grant, Rajiv Patni is shown as holding 275,000 stock options for Septerna common stock associated with this award. These options are subject to the stated vesting schedule and expiration date.

Was Rajiv Patni’s Septerna (SEPN) option grant made under a Rule 10b5-1 trading plan?

The disclosure indicates no Rule 10b5-1 trading plan for this transaction. The grant is reported as an award of stock options, not as part of a pre-arranged trading program for market purchases or sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 05:08 PM Accepted by SEC EDGAR 09/10/2026 - 05:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patni Rajiv

(Last) (First) (Middle)

C/O SEPTERNA, INC.

250 EAST GRAND AVENUE

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Septerna, Inc. [ SEPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$37.37	09/08/2026		A		275,000		(1)	09/07/2036	Common Stock	275,000	$0	275,000	D

Explanation of Responses:

1. 25% of the shares underlying this option will vest on August 24, 2027, and the remaining 75% of the shares underlying this option will vest in thirty-six substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

	/s/ Mark A. Wilson, Attorney-in-Fact	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)